MedTrace Logo

Cohort Study of Honghua Xiaoyao Tablets in the Treatment of Premenstrual Syndrome Based on Target Trial Emulation Framework

NCT07171814 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 266

Last updated 2025-09-15

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Honghua Xiaoyao tablets in the treatment of premenstrual syndrome, and the results were further analyzed and evaluated by target trial simulation (TTE) framework.

Conditions

  • Premenstrual Syndrome

Interventions

DRUG

Honghua Xiaoyao tablets

The non-exposed group (patients who did not receive Honghua Xiaoyao Tablets or other targeted drug treatments) only received routine clinical observation, and no drug intervention was applied after obtaining informed consent. If patients need to withdraw from the study due to their condition during the study period, on the premise that the patients have given full informed consent, doctors shall recommend other treatment regimens in accordance with clinical standards (when necessary, first-line drugs such as selective serotonin reuptake inhibitors (SSRIs) may be selected for intervention).

Sponsors & Collaborators

  • Chaoyangmen Community Health Service Center of Dongcheng District in Beijing

    collaborator UNKNOWN

  • Hepingli Community Health Service Center,Dongcheng District,Beijing

    collaborator UNKNOWN

  • Lianxin Wang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-07-30
Completion
2027-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07171814 on ClinicalTrials.gov